Mizuho raised the firm’s price target on Neurocrine (NBIX) to $175 from $146 and keeps a Neutral rating on the shares. The firm updated the company’s model with an extended loss of exclusivity to 2040 from 2037.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $188 from $183 at Stifel
- Neurocrine price target raised to $180 from $160 at RBC Capital
- Neurocrine price target raised to $200 from $175 at TD Cowen
- Neurocrine’s Strong Market Position and Growth Potential: Buy Rating Affirmed
- Neurocrine Extends Eiry W. Roberts’ Employment Term